JAK inhibitors, such as ruxolitinib (Jakafi®), are changing the landscape of treatment for myeloproliferative neoplasms (MPNs). Dr. Bart Scott from Seattle Cancer Care Alliance discusses how JAK inhibitors work to treat MPNs, new JAK inhibitors currently in trial, and why it’s an exciting time for research in the MPN field.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…